Acute hepatic porphyria (AHP) refers to a family of rare genetic diseases that affect the production of heme, a component of red blood cells. It can cause life threatening complications. AHP can cause ...

Acute hepatic porphyria, or AHP, is a group of rare genetic conditions that affect how the body makes a natural substance called heme. Heme is produced in the liver and is essential for many important ...

Alnylam Pharmaceuticals has put its dancing shoes on to raise awareness of the experience of living with acute hepatic porphyria (AHP). A recently released patient storytelling initiative by the ...

– The Alnylam Act ® program is a genetic testing initiative designed to enable improved patient diagnosis of three rare, devastating, and life-threatening genetic diseases – – Through the Alnylam Act ...

Acute hepatic porphyria is caused by defects in heme biosynthesis enzymes; the accumulation of neurotoxic heme intermediates causes injury to the nervous system and other organs. Attacks typically ...

Givlaari (givosiran) is a prescription drug approved to treat acute hepatic porphyria (AHP). Givlaari comes as an injection given under the skin by a healthcare provider. Specifically, Givlaari is ...

The program, called Alnylam Act ®, provides genetic testing for the diagnosis of acute hepatic porphyria, primary hyperoxaluria type 1 (PH1), and hereditary ATTR (hATTR) amyloidosis. Along with ...